文献速递前列腺癌

接受雄激素受体信号抑制剂治疗的前列腺癌患者的心血管事件:系统评价、荟萃分析与网状荟萃分析

Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-09-05

该系统评价与网状荟萃分析纳入26项随机对照试验,评估阿比特龙、阿帕他胺、达罗他胺和恩扎卢胺治疗前列腺癌患者的心血管事件风险。雄激素受体通路抑制剂(ARPIs)联合雄激素剥夺治疗(ADT)增加心脏疾病、心力衰竭、心房颤动和高血压风险,每种ARPIs具有不同的心血管事件特征。

要点

  • ARPIs联合ADT增加≥3级心脏疾病、心力衰竭、心房颤动和高血压风险。
  • 阿比特龙增加≥3级心脏疾病和高血压风险。
  • 恩扎卢胺增加≥3级心房颤动和高血压风险。

核心结论

  • ARPIs联合ADT增加心脏疾病(包括缺血性心脏病和心房颤动)及高血压风险。
  • 每种ARPIs表现出不同的心血管事件特征。
  • 对接受ARPIs联合ADT治疗的患者,仔细选择患者并警惕监测心血管问题至关重要。

研究设计与样本

  • 系统评价、荟萃分析与网状荟萃分析,纳入26项随机对照试验。
  • 2023年8月检索PubMed、Scopus和Web of Science数据库,纳入分析阿比特龙、阿帕他胺、达罗他胺和恩扎卢胺治疗前列腺癌患者的随机对照试验。

主要发现

  • ARPIs与≥3级心脏疾病风险增加相关(RR:1.74,95% CI:1.13-2.68,p=0.01)。
  • ARPIs与≥3级心力衰竭风险增加相关(RR:2.49,95% CI:1.05-5.91,p=0.04)。
  • ARPIs与≥3级心房颤动风险增加相关(RR:2.15,95% CI:1.14-4.07,p=0.02)。
  • ARPIs与≥3级高血压风险增加相关(RR:2.06,95% CI:1.67-2.54,p<0.01)。
  • 网状荟萃分析显示,阿比特龙增加≥3级心脏疾病风险(RR:2.40,95% CI:1.42-4.06)和高血压风险(RR:2.19,95% CI:1.77-2.70);恩扎卢胺增加≥3级心房颤动风险(RR:3.17,95% CI:1.05-9.58)和高血压风险(RR:2.30,95% CI:1.82-2.92)。

临床怎么用

  • 作者认为,对接受ARPIs联合ADT治疗的患者,仔细选择患者并警惕监测心血管问题至关重要。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Androgen-receptor pathway inhibitors (ARPIs) have dramatically changed the management of advanced/metastatic prostate cancer (PCa). However, their cardiovascular toxicity remains to be clarified. OBJECTIVE: To analyze and compare the risks of cardiovascular events secondary to treatment of PCa patients with different ARPIs. METHODS: In August 2023, we queried PubMed, Scopus, and Web of Science databases to identify randomized controlled studies (RCTs) that analyze PCa patients treated with abiraterone, apalutamide, darolutamide, and enzalutamide. The primary outcomes of interest were the incidence of cardiac disorder, heart failure, ischemic heart disease (IHD), atrial fibrillation (AF), and hypertension. Network meta-analyses (NMAs) were conducted to compare the differential outcomes of each ARPI plus androgen deprivation therapy (ADT) compared to standard of care (SOC). RESULTS: Overall, 26 RCTs were included. ARPIs were associated with an increased risk of cardiac disorders (RR: 1.74, 95% CI: 1.13-2.68, p = 0.01), heart failure (RR: 2.49, 95% CI: 1.05-5.91, p = 0.04), AF (RR: 2.15, 95% CI: 1.14-4.07, p = 0.02), and hypertension (RR: 2.06, 95% CI: 1.67-2.54, p < 0.01) at grade ≥3. Based on NMAs, abiraterone increased the risk of grade ≥3 cardiac disorder (RR:2.40, 95% CI: 1.42-4.06) and hypertension (RR:2.19, 95% CI: 1.77-2.70). Enzalutamide was associated with the increase of grade ≥3 AF(RR: 3.17, 95% CI: 1.05-9.58) and hypertension (RR:2.30, 95% CI: 1.82-2.92). CONCLUSIONS: The addition of ARPIs to ADT increases the risk of cardiac disorders, including IHD and AF, as well as hypertension. Each ARPI exhibits a distinct cardiovascular event profile. Selecting patients carefully and vigilant monitoring for cardiovascular issues is imperative for those undergoing ARPI + ADT treatment.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Matsukawa A, Yanagisawa T, Parizi MK, et al. Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis. Prostate Cancer Prostatic Dis. 2024. PMID: 39237679. doi:10.1038/s41391-024-00886-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。